MLN 8054

Drug Profile

MLN 8054

Alternative Names: MLN8054

Latest Information Update: 12 Nov 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Liver cancer; Solid tumours

Most Recent Events

  • 14 May 2008 Millennium Pharmaceuticals has been acquired by Takeda
  • 12 Jun 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events and Cancer therapeutic trials sections
  • 01 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the adverse events and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top